IL17A抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06451(IL17A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

IL-17A, a pro-inflammatory cytokine primarily produced by Th17 cells, plays a pivotal role in host defense and autoimmune diseases. It activates downstream signaling via IL-17 receptors, inducing chemokines and antimicrobial peptides that recruit neutrophils and promote inflammation. Dysregulated IL-17A is implicated in chronic inflammatory conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and multiple sclerosis.

IL-17A-targeting antibodies emerged as therapeutic agents to block this pathway. These monoclonal antibodies bind IL-17A, preventing its interaction with receptors and interrupting inflammatory cascades. Secukinumab (anti-IL-17A) and ixekizumab (anti-IL-17A) were among the first approved biologics, demonstrating high efficacy in psoriasis by rapidly reducing skin lesions and joint inflammation. Their success validated IL-17A as a key therapeutic target.

Research continues to explore IL-17A's role in other diseases, including inflammatory bowel disease and rheumatoid arthritis, though results vary due to complex cytokine networks. Safety profiles generally favor IL-17A inhibitors over broader immunosuppressants, but risks like candidiasis remain due to impaired mucosal immunity. Ongoing studies aim to optimize dosing, expand indications, and identify biomarkers for personalized treatment. IL-17A antibodies represent a paradigm shift in managing Th17-driven pathologies, balancing targeted action with systemic immune modulation.